Coronary vasodilatation and improved myocardial lactate metabolism after angiotensin converting enzyme inhibition with cilazapril in patients with congestive heart failure
- PMID: 1683143
- DOI: 10.1016/0002-8703(91)90581-2
Coronary vasodilatation and improved myocardial lactate metabolism after angiotensin converting enzyme inhibition with cilazapril in patients with congestive heart failure
Abstract
The effects of angiotensin converting enzyme inhibition on systemic and coronary hemodynamics and on myocardial lactate metabolism were investigated before and 2 and 6 hours after cilazapril at rest and during supine submaximal exercise in 10 patients with New York Heart Association class II or III chronic congestive heart failure. Angiotensin converting enzyme inhibition, indicated by a significant increase in plasma renin activity, resulted in significant reductions in blood pressure and systemic vascular resistance. Myocardial oxygen demand decreased (resting double product 10.9 +/- 3.7 vs 12.2 +/- 3.8 mm Hg beats/min 10(-3); p less than 0.05), but coronary sinus blood flow remained unchanged and calculated coronary resistance decreased (0.45 vs 0.5 units, rest 6 hours; p less than 0.05) suggesting coronary vasodilatation. Changes in coronary vascular resistance were directly related to changes in systemic vascular resistance (r = 0.75, p less than 0.5). Myocardial lactate extraction increased at rest (47 +/- 60 vs 134 +/- 132 mumol/min; p less than 0.5) and during exercise (27 +/- 54 vs 491 +/- 317 mumol/min; p less than 0.05) both in patients with coronary artery disease (n = 5) and idiopathic dilated cardiomyopathy (n = 5). Resting lactate production was converted to lactate extraction in two patients with coronary artery disease. Neither plasma catecholamine nor atrial natriuretic peptide concentrations changed significantly. The results suggest coronary vasodilation and improved aerobic myocardial metabolism by angiotensin converting enzyme inhibition in patients with congestive heart failure.
Similar articles
-
Contrasting peripheral short-term and long-term effects of converting enzyme inhibition in patients with congestive heart failure. A double-blind, placebo-controlled trial.Circulation. 1989 Mar;79(3):491-502. doi: 10.1161/01.cir.79.3.491. Circulation. 1989. PMID: 2521816 Clinical Trial.
-
Enalaprilat, a new parenteral angiotensin-converting enzyme inhibitor: rapid changes in systemic and coronary hemodynamics and humoral profile in chronic heart failure.J Am Coll Cardiol. 1987 May;9(5):1131-8. doi: 10.1016/s0735-1097(87)80318-2. J Am Coll Cardiol. 1987. PMID: 3033043
-
Cilazapril in congestive heart failure. A pilot study.Drugs. 1991;41 Suppl 1:54-61. doi: 10.2165/00003495-199100411-00010. Drugs. 1991. PMID: 1712273 Clinical Trial.
-
Neurohormonal activation and congestive heart failure: today's experience with ACE inhibitors and rationale for their use.Eur Heart J. 1995 Dec;16 Suppl N:65-72. doi: 10.1093/eurheartj/16.suppl_n.65. Eur Heart J. 1995. PMID: 8682064 Review.
-
Role of angiotensin-converting enzyme inhibitors in congestive heart failure.Heart Lung. 1990 Sep;19(5 Pt 1):505-11. Heart Lung. 1990. PMID: 2211159 Review.
Cited by
-
Potential Antithrombotic and Fibrinolytic Properties of the Angiotensin Converting Enzyme Inhibitors.J Thromb Thrombolysis. 1995;1(3):251-257. doi: 10.1007/BF01060734. J Thromb Thrombolysis. 1995. PMID: 10608002
-
Antianginal and anti-ischemic effects of nisoldipine and ramipril in patients with syndrome X.Clin Cardiol. 1999 May;22(5):361-5. doi: 10.1002/clc.4960220513. Clin Cardiol. 1999. PMID: 10326170 Free PMC article. Clinical Trial.
-
Reduction of ischemic events with angiotensin-converting enzyme inhibitors: lessons and controversy emerging from recent clinical trials.Cardiovasc Drugs Ther. 1995 Feb;9(1):89-102. doi: 10.1007/BF00877749. Cardiovasc Drugs Ther. 1995. PMID: 7786840 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical